# Retatrutide References: Full Citation List

> Full bibliography for Telehealth Retatrutide research digest — Phase 1b through Phase 2 trials, structural biology, meta-analyses, and 2024-2026 studies. DOIs and PubMed links.

Every claim on this site traces back to one of these sources.

## Primary trials and structural studies

Full citation list below. DOIs link to the publisher; PubMed links are provided for all PMID-indexed articles. Citations are numbered as used across this site.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Yin Y, et al. Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of diabetes. 2025;17(4):e70082. https://doi.org/10.1111/1753-0407.70082
[8] Melson E, et al. What is the pipeline for future medications for obesity? International journal of obesity (2005). 2025;49(3):433-451. https://doi.org/10.1038/s41366-024-01473-y
[9] Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj metabolic health and disease. 2024;2(1):31. https://doi.org/10.1038/s44324-024-00030-5
[10] Deravi M, et al. The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 2024;40(6):300-305. https://doi.org/10.1177/87551225241285326
[11] Kusminski CM, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829-3853. https://doi.org/10.1016/j.cell.2024.06.003
[12] Pillai AA, et al. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. Cardiology in review. 2026. https://doi.org/10.1097/CRD.0000000000001310
[13] Pearson MJ, et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2026. https://doi.org/10.1210/clinem/dgag201
[14] Basile C, et al. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. European journal of preventive cardiology. 2026. https://doi.org/10.1093/eurjpc/zwaf560
[15] Wen Y, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes, obesity & metabolism. 2025. https://doi.org/10.1111/dom.16661

---

An instrument readout of the Phase 1–3 retatrutide trial record — cardiometabolic endpoints logged to primary source, gaps noted in plain view, and no clinic, prescription, or product behind the screen.